Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCORE FL-1: epcoritamab plus rituximab + lenalidomide versus R2 in relapsed or refractory follicular lymphoma
MOH_2022-07-10_011882Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epcoritamab in follicular lymphoma (FL) (3 arms), sponsored by AbbVie Inc. Started Jul 2022; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2022-07-10_011882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-10_011882.